Actuate Therapeutics, Inc. (ACTU)

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers. Its research focuses on glycogen synthase kinase-3 beta (GSK-3B), an enzyme involved in tumor growth, resistance to chemotherapy and suppression of the immune response against cancer.

The company's lead candidate is elraglusib, an intravenous GSK-3B inhibitor being studied in combination with chemotherapy in patients with metastatic pancreatic cancer, as well as in other solid tumors and pediatric cancers. It is also working on an oral formulation of the drug. Actuate Therapeutics is based in Fort Worth, Texas, and its shares began trading on Nasdaq after its 2024 initial public offering.